文章：

卵巢癌症基因治疗中的腺相关病毒载体

AAV for ovarian cancer gene therapy 

原文发布日期：2025-06-20 

英文摘要：

Recent advancements in ovarian cancer treatment, particularly with PARP inhibitors, have markedly enhanced the recurrence-free interval, shifting the treatment paradigm and increasing treatment success in patients with BRCA mutations or HRD (homologous recombination deficiency). However, a significant proportion of cases experience relapse, resulting in poorer long-term survival rates when compared to other female cancers, such as breast cancer. This review explores the potential of adeno-associated virus (AAV) vectors for gene therapy in ovarian cancer and examines rational gene therapy strategies by categorizing them based on target cells and target genes to determine the most effective approach for ovarian cancer treatment. Specifically, it examines strategies such as anti-angiogenesis and immune modulation, highlighting the strategy of gene supplementation to hinder ovarian cancer progression. Innovations in AAV capsid design now allow for targeted delivery, focusing on ovarian cancer stem cells (CSCs) identified by specific markers. Additionally, leveraging DNA sequencing technologies enhances the identification and incorporation of therapeutic genes into AAV vectors, promising new avenues for ovarian cancer gene therapy. 

摘要翻译：

卵巢癌治疗领域的最新进展，尤其是PARP抑制剂的应用，显著延长了无复发生存期，改变了治疗范式，并提高了BRCA突变或HRD（同源重组缺陷）患者的治疗成功率。然而，相当比例的患者仍会复发，导致其长期生存率低于乳腺癌等其他女性癌症。本综述探讨了腺相关病毒（AAV）载体在卵巢癌基因治疗中的应用潜力，通过按靶细胞和靶基因分类的研究策略，系统分析了针对卵巢癌的最有效基因治疗路径。重点研究了抗血管生成和免疫调节等策略，并着重探讨了通过基因补充抑制卵巢癌进展的治疗方案。AAV衣壳设计的创新实现了靶向递送，专注于通过特定标志物识别的卵巢癌干细胞（CSCs）。此外，DNA测序技术的运用增强了治疗性基因的识别与AAV载体整合能力，为卵巢癌基因治疗开辟了新途径。

原文链接：

AAV for ovarian cancer gene therapy